References
- Coresh J. Update on the Burden of CKD. Journal of the American Society of Nephrology 2017; 28:1020–2. https://doi.org/10.1681/ASN.2016121374
- Agarwal SK. Chronic kidney disease and its prevention in India. Kidney International Supplement 2005;68: S41-5. https://doi.org/10.1111/j.1523-1755.2005.09808.Wang H, Naghavi M, Allen C, et al. Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2015; 388:1459–544. Benz K, Hilgers KF, Daniel C, Amann K. Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. Int J Nephrol. 2018:4310379. https://doi:10.1155/2018/4310379.
- Bulbul MC, Dagel T, Afsar B, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purification 2018; 46:144-52, https://doi.org/10.1159/000488816
- Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology 1998;9:S16-23. https//doi:10.1053/ajkd.1998.v32.pm9820470
- Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. Journal of the American Society of Nephrology 2001; 12:1079-84. https/doi:10.1681/ASN.V1251079
- Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. American Journal of Kidney Diseases 1996; 27:347-54. https//doi:10.1016/s0272-6386(96)90357-1
- Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clinical Journal of the American Society of Nephrology. 2008; 3:920–9. https//doi:10.2215/CJN.04571007
- Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia – beyond coronary heart disease. Seminars in Dialysis 2008; 21:308–18. https//doi:10.1111/j.1525139X.2008.00454.x
- Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney International 2009; 75:771–3. https//doi:10.1038/ki.2009.35
- Yilmaz BA, Mete T, Dincer I, et al. Predictors of left ventricular hypertrophy in patients with chronic kidney disease. Renal Failure 2007;29: 303-7. httpss//DOI:10.1080/08860220601166529
- Cottone S, Nardi E, Mulè G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clinical Nephrology 2007; 67:209-16. https//doi:10.5414/cnp67209
- Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? Journal of the American Society of Nephrology. 2006; 17:S255-61. https//doi:10.1681/ASN.2006080923
- Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337:116-22. https//doi:10.1097/MAJ.0b013e3181815498
- Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-52. https//doi:10.1161/CIRCULATIONAHA.108.844506
- Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984; 4:1222-30. https//doi:10.1016/s0735-1097(84)80141-2
- Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International 2008; 74:1461–7. https//doi:10.1038/ki.2008.484
- Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic pre-dialysis CKD. American Journal of Kidney Diseases 2005; 46:320-7. https//doi:10.1053/j.ajkd.2005.04.031
- Kimura T, Iio K, Obi Y, Hayashi T. Left ventricular hypertrophy in pre-dialysis chronic kidney disease: impact of cardiomuscular stress markers. Nippon Jinzo Gakkai Shi 2007; 49:1007-13.b. https://doi.org/10.14842/jpnjnephrol1959.49.1007
- Brancaccio D, Cozzolino M. The mechanism of calcium deposition in soft tissues. Contributions to Nephrology 2005; 149: 279–86. https//doi:10.1159/000085689
- Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney International 2014; 85:142-50. doi: 10.1038/ki.2013.271
- Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009; 45:1161-8. https//doi:10.1016/j.bone.2009.08.008
- Zhou C, Wang F, Wang JW, et al. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chinese Medical Journal 2016; 129:2275-80. https//doi:10.4103/0366-6999.190678
- Chue CD, Edwards NC, Moody WE, et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012; 98:219-24. https//doi:10.1136/heartjnl-2011-300570
- Wahl P, Wolf M. FGF23 in chronic kidney disease. Advances in Experimental Medicine and Biology 2012; 728:107-25. https//doi:10.1007/978-1-4614-0887-1_8
- Isakova T, Xie H, Yang W, et al. Chronic Renal Insunjciency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-9. https//doi:10.1001/jama.2011.826
- Liu X, Xie R, Liu S. Rat parathyroid hormone 1–34 signals through the MEK/ERK pathway to induce cardiac hypertrophy. Int J Med Res. 2008;36:942–50.
- Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-408. https//doi:10.1172/JCI46122. Epub 2011 Oct 10.
- Nielsen TL, Plesner LL, Warming PE, et al. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia (Engl Ed) 2019; 39:258-68. https//doi:10.1016/j.nefro.2018.10.007">https//doi:10.1016/j.nefro.2018.10.007